Advisory firm focused on commercialization and sales scale-up for biotech, medtech, healthtech and lab instrumentation companies
◼︎ We deliver integrated solutions to commercialise innovation and scale businesses
◼︎ We bridge scientific innovation with capital and execution, enabling companies to become scalable, investable businesses
◼︎ Our focus is clear: turning innovation into revenue
About
-
IDB was founded by two long-time friends who built complementary careers — Dmitri in international biotech sales, Igor in institutional investment and strategic management. Dmitri holds a PhD in molecular biology (UNC Chapel Hill and Max Planck Institute for Biophysical Chemistry, Goettingen) and has spent 23+ years building sales teams across EMEA and APAC.
Igor spent 20+ years allocating capital and working with JPMorgan, UBS, Morgan Stanley, and Goldman Sachs, managing portfolios above USD 2 billion.
Around them, IDB has built a global network of senior commercial consultants focused on biotech and medtech sales — across Europe, the US and APAC — embedding regionally wherever a client needs traction.
-
The biotech commercial gap is the main gap we close.
Biotech startups often have breakthrough science but no commercial engine — that’s where most fail. Traditional advisory stops at recommendations, while we execute as an embedded fractional CRO, BDM and CFO from day one.
We combine PhD-level biotech expertise, institutional investment experience, AI-enabled outreach, and hands-on business development in one integrated team. We build pipeline, prepare the financial story for institutional capital, and stay involved through execution — not just strategy.
Unlike generalist consultants, we connect science, commercial traction, capital, and AI-driven sales acceleration under one roof, with both founders actively involved in every engagement.
With offices in Australia and Germany, IDB operates across key APAC and European biotech markets, enabling relevant local access, cross-border execution, and institutional connectivity
Why IDB
Traditional advisory
× Strategy decks with no execution
× Generalist consultants - no biotech depth
× Separate advisors for science, commercial, capital
× Manual outreach - slow and expensive
× Advice stops at the report
× You still need to build the team yourself
IDB Consulting
✓ We execute - embedded CRO/BDM/CFO from day one
✓ PhD-level biotech expertise + investment background
✓ Science, commercial, capital, and Al - integrated
✓ Al sales agents accelerate pipeline 3-5x sales
✓ We build your commercial engine, not just advise
✓ Sales team stays with you after handoff
Our services
Commercialisation
90% of biotech startups fail to reach commercial scale. The science is usually strong — the commercial engine is missing. That gap is what we close.
Market positioning
Pricing strategy
KOL & customer relationships
GTM leadership
Pipeline & deal coaching
Senior sales hiring
Product demos & qualification
Proposal & RFP management
Customer expansion
Sales operations & reporting
Negotiation & deal closing
In-flight deal management
Cross-sell & upsell to accounts
Commercial Engine
Financial strategy
Scenario modelling
Internal finance function
Reporting system
Investor narrative
Investor road show
Fundraising management
GP & investor introductions
Board participation
Shareholder communication
Post investment strategy
Capital Strategy
Partner strategy
Pharma partnerships
Cross-border channel due diligence
Cross-border relationship management
Deal structuring
Buyer negotiations
Distrubutors due diligence
Exit support
In-person strategic meetings
Strategic Growth
Success in biotech requires the right support
Blueprint Genetics
NGS genetic diagnostics
→ Launch: 2012
→ Strategy: Niche (rare diseases)
→ Growth Model: Controlled / organic
→ Debt Level: Low
→ Margins: High (value-added)
→ Product Complexity: Advanced interpretation
→ Outcome: Acquired for >$100M (2020)
Invitae
NGS genetic diagnostics
→ Launch: 2010
→ Strategy: Mass market
→ Growth Model: Aggressive via M&A
→ Debt Level: High
→ Margins: Low / negative
→ Product Complexity: Standardized tests
→ Outcome: Bankruptcy (2024)
Case Studies
Designed and executed European GTM strategy for a neurobiology lab equipment company targeting UK, DACH and Scandinavia
40+ Target neuroscience labs identified
15 Qualified discussions with research groups
5 Priority European markets activated
Client
→ US Company developing equipment for neurobiology laboratories
→ Products: micromanipulators and patch‑clamp systems
→ Customers: neuroscience labs in universities and research institutes
What we did
→ European GTM strategy and priority market selection
→ Segmentation of neuroscience research labs
→ Distributors and partnerships negotiations
→ Target account list and outreach framework
Strategic Outcome
Successfull commercial expansion across key European neuroscience hubs
Expanded APAC market presence for a European monoclonal antibody research supplier through Fractional CRO leadership
4 Priority APAC markets targeted
30+ Research institutes & biotech accounts identified
5 Strategic distributor / partner discussions
Client
→ European biotech company producing monoclonal antibodies
→ Products used for life science and biomedical research
→ Customers: research institutes, biotech companies, CROs
What we did
→ Fractional CRO leadership for APAC expansion
→ Market prioritization across key APAC life science hubs
→ Distributor and partner strategy for research markets
→ Commercial pipeline development and partner outreach
Strategic Outcome
Established a structured APAC commercial and distributor pipeline enabling scalable regional growth in the research reagents market
